Citadel Advisors’s Lifecore Biomedical LFCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $519K | Buy |
+98,870
| New | +$498K | ﹤0.01% | 9773 |
|
|
2026
Q1 | – | Sell |
-18,116
| Closed | -$125K | – | 13664 |
|
|
2025
Q4 | $148K | Sell |
18,116
-48,636
| -73% | -$360K | ﹤0.01% | 11334 |
|
|
2025
Q3 | $491K | Buy |
66,752
+37,363
| +127% | +$283K | ﹤0.01% | 9184 |
|
|
2025
Q2 | $239K | Sell |
29,389
-1,134
| -4% | -$7.64K | ﹤0.01% | 10313 |
|
|
2025
Q1 | $215K | Buy |
+30,523
| New | +$190K | ﹤0.01% | 10315 |
|
|
2024
Q3 | – | Sell |
-42,437
| Closed | -$218K | – | 14796 |
|
|
2024
Q2 | $218K | Buy |
+42,437
| New | +$251K | ﹤0.01% | 9755 |
|
|
2023
Q4 | – | Sell |
-75,321
| Closed | -$568K | – | 14830 |
|
|
2023
Q3 | $568K | Buy |
75,321
+6,915
| +10% | +$63.2K | ﹤0.01% | 7787 |
|
|
2023
Q2 | $661K | Buy |
+68,406
| New | +$418K | ﹤0.01% | 7319 |
|
|
2023
Q1 | – | Sell |
-83,755
| Closed | -$467K | – | 15141 |
|
|
2022
Q4 | $543K | Buy |
+83,755
| New | +$690K | ﹤0.01% | 8068 |
|
|
2022
Q3 | – | Sell |
-17,539
| Closed | -$175K | – | 13169 |
|
|
2022
Q2 | $175K | Sell |
17,539
-28,321
| -62% | -$280K | ﹤0.01% | 10841 |
|
|
2022
Q1 | $531K | Buy |
+45,860
| New | +$511K | ﹤0.01% | 9247 |
|
|
2021
Q3 | – | Sell |
-50,102
| Closed | -$545K | – | 14283 |
|
|
2021
Q2 | $564K | Sell |
50,102
-10,526
| -17% | -$121K | ﹤0.01% | 9791 |
|
|
2021
Q1 | $643K | Buy |
60,628
+1,833
| +3% | +$20.6K | ﹤0.01% | 9128 |
|
|
2020
Q4 | $638K | Buy |
+58,795
| New | +$607K | ﹤0.01% | 7685 |
|
|
2020
Q2 | – | Sell |
-23,340
| Closed | -$203K | – | 10202 |
|
|
2020
Q1 | $203K | Buy |
23,340
+10,085
| +76% | +$105K | ﹤0.01% | 7987 |
|
|
2019
Q4 | $150K | Sell |
13,255
-5,017
| -27% | -$53.4K | ﹤0.01% | 8363 |
|
|
2019
Q3 | $199K | Buy |
18,272
+6,416
| +54% | +$69.8K | ﹤0.01% | 8159 |
|
|
2019
Q2 | $111K | Buy |
+11,856
| New | +$120K | ﹤0.01% | 8499 |
|
|
2018
Q4 | – | Sell |
-14,207
| Closed | -$205K | – | 9490 |
|
|
2018
Q3 | $205K | Buy |
+14,207
| New | +$196K | ﹤0.01% | 8181 |
|
|
2017
Q4 | – | Sell |
-14,552
| Closed | -$188K | – | 8237 |
|
|
2017
Q3 | $188K | Buy |
+14,552
| New | +$192K | ﹤0.01% | 6741 |
|
|
2016
Q4 | – | Sell |
-10,270
| Closed | -$138K | – | 7586 |
|
|
2016
Q3 | $138K | Buy |
+10,270
| New | +$124K | ﹤0.01% | 6525 |
|
|
2016
Q1 | – | Sell |
-20,107
| Closed | -$238K | – | 7421 |
|
|
2015
Q4 | $238K | Sell |
20,107
-14,421
| -42% | -$177K | ﹤0.01% | 5557 |
|
|
2015
Q3 | $403K | Buy |
34,528
+3,757
| +12% | +$49.8K | ﹤0.01% | 5110 |
|
|
2015
Q2 | $444K | Buy |
+30,771
| New | +$444K | ﹤0.01% | 5165 |
|
|
2014
Q4 | – | Sell |
-29,036
| Closed | -$356K | – | 8621 |
|
|
2014
Q3 | $356K | Buy |
29,036
+4,044
| +16% | +$50.5K | ﹤0.01% | 5048 |
|
|
2014
Q2 | $312K | Sell |
24,992
-37,237
| -60% | -$438K | ﹤0.01% | 5023 |
|
|
2014
Q1 | $695K | Buy |
62,229
+33,774
| +119% | +$370K | ﹤0.01% | 3901 |
|
|
2013
Q4 | $345K | Buy |
28,455
+1,510
| +6% | +$18K | ﹤0.01% | 4459 |
|
|
2013
Q3 | $329K | Buy |
+26,945
| New | +$376K | ﹤0.01% | 4256 |
|
Other funds holding LFCR
WC
LPAM
GRIM
3C
QOP
Citadel Advisors's LFCR Position: Q2 2026 in Review
Citadel Advisors opened a new position in Lifecore Biomedical (LFCR) in Q2 2026: 98,870 shares worth $519K. The stake represents ﹤0.01% of the portfolio and ranks #9773 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LFCR as recently as Q4 2025.
Citadel Advisors first reported a position in LFCR in Q3 2013 and has held it in 29 quarters since. The position peaked at $695K in Q1 2014. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.
- Citadel Advisors held 98,870 shares of Lifecore Biomedical worth $519K as of Q2 2026.
- Lifecore Biomedical was a new Citadel Advisors position in Q2 2026.
- Lifecore Biomedical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9773 holding.
- Citadel Advisors first reported a position in Lifecore Biomedical in Q3 2013 and has held it in 29 quarters since.
- Citadel Advisors's Lifecore Biomedical position peaked at $695K in Q1 2014.
- 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.